Understanding the Financial Health of Aileron Therapeutics, Inc. (ALRN)

Publicly-traded company Aileron Therapeutics, Inc. (NASDAQ:ALRN) had a closing price of $0.41 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $6.33, this means that the stock is underpriced by 93.523%. In the past 52 weeks the company’s stock price has moved within the range of $0.40 to $2.60.

This particular stock’s 5-day moving average is 0.43, its 20-day moving average is 0.54 and its 100-day moving average is 0.69. Aileron Therapeutics, Inc. (ALRN) currently has 27810 shares outstanding, which means that its market capitalization is $11.25M.


The Details: Aileron Therapeutics, Inc. (ALRN) Financial Health

We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, Aileron Therapeutics, Inc. Return on Assets is -88.10% .


What Does Wall Street Say about Company?

When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for ALRN is Buy . Out of 4 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 4 rated it a Buy.

Three months ago, on the other hand, the average analyst rating for Aileron Therapeutics, Inc. (ALRN) was a – – from a survey of 0 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 0 rated it a Buy.


Understanding Profitability at Aileron Therapeutics, Inc. (ALRN)

A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by Aileron Therapeutics, Inc., for the quarter ending on 09/2019, the company posted EPS of -0.24. The average estimate of Wall Street analysts had projected -0.22.